Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 2/20 | 0.32 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | RBP4 | P02753 | 3/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5724090 | 0.88 | SCD (0.34) | SCDSCD5RIPK1RBP4HCRTR1 | |
| SCHEMBL5724174 | 0.87 | RIPK1 (0.41) | SCDSCD5RIPK1RBP4HCRTR1 | |
| SCHEMBL5724367 | 0.84 | DGAT2 (0.35) | SCD5RIPK1RBP4HCRTR1HCRTR2 | |
| SCHEMBL5724188 | 0.84 | SCD (0.32) | SCDSCD5RIPK1RBP4HCRTR1 | |
| SCHEMBL5724344 | 0.83 | HTR2C (0.37) | SCDSCD5TP53 | |
| SCHEMBL5724981 | 0.82 | TTR (0.35) | RBP4HCRTR1HCRTR2 | |
| SCHEMBL5723594 | 0.81 | RIPK1 (0.37) | SCD5RIPK1HCRTR1HCRTR2 | |
| SCHEMBL5723733 | 0.80 | ALDH1A1 (0.39) | — | |
| SCHEMBL5724415 | 0.79 | DAGLA (0.36) | RBP4HCRTR1HCRTR2 | |
| SCHEMBL5724473 | 0.78 | FGFR1 (0.34) | RIPK1RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1340757-B1 | 1-METHYLCARBAPENEM DERIVATIVES | SANKYO CO (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-7001897-B2 | 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-02-21 | — | — | US | disclosed |
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1340757-A1 | 1-METHYLCARBAPENEM DERIVATIVES | Sankyo Company, Limited (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | CD14, CPT1A, ACMSD | SCD 54/4885SCD5 95/4885RIPK1 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.